2023 World Conference on Lung Cancer (Posters)-EP10.01. First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study

EP10.01. First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses a retrospective study that aimed to evaluate the efficacy of first-line treatments for patients with metastatic lung adenocarcinoma and malignant pleural effusion (MPE) who do not have a driver gene mutation. The study analyzed data from 369 patients who received either standard platinum-based doublet chemotherapy (CT), CT plus immune checkpoint inhibitors (CTICI), or CT plus Bevacizumab (CTBev) between January 2012 and October 2022. <br /><br />The results showed that CTBev and CTICI had a significantly better local-control rate (LCR) for MPE compared to CT alone, with CTBev being the potentially optimal regimen. CTICI was found to have superior outcomes in patients with PD-L1 expression of ≥50%. LCR of MPE was found to significantly prolong survival, with patients experiencing longer progression-free survival (PFS) and overall survival (OS) compared to those receiving CT alone. PFS and OS were significantly longer in the CTICI/CTBev population compared to the CT population. CTBev had superior PFS and OS compared to CTICI/CT in patients with PD-L1 expression of 1-49%, whereas CTICI had longer PFS and OS in the PD-L1 ≥50% population.<br /><br />Overall, the study concludes that the combination of CT and Bev or ICIs had better control of MPE and significantly longer survival compared to chemotherapy alone in patients with driver-gene negative metastatic lung adenocarcinoma and MPE. The expression of PD-L1 may influence the choice between Bevacizumab or ICIs in combination therapy. The study suggests that further prospective investigation is necessary.

Asset Subtitle

Yuanyuan Zhao

Meta Tag

Speaker Yuanyuan Zhao

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

retrospective study

efficacy

first-line treatments

metastatic lung adenocarcinoma

malignant pleural effusion

driver gene mutation

platinum-based doublet chemotherapy

immune checkpoint inhibitors

Bevacizumab

local-control rate